By Turna Ray

Following multiple accounts from payors about rising levels of inappropriate BRCA testing to gauge which women are at higher hereditary risk for breast and ovarian cancer, national insurer Aetna said last week that it will survey testing patterns among women treated in a community healthcare setting. The findings of the two-year study, which payors will surely be closely reviewing, could impact how BRACAnalysis, Myriad Genetics' flagship product, is covered by insurers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.